DISTRIBUTION AND SUBLICENSE AGREEMENTDistribution and Sublicense Agreement • December 9th, 2016 • Braeburn Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
THIS DISTRIBUTION AND SUBLICENSE AGREEMENT (this “Agreement”), dated as of February 1, 2016 (the “Effective Date”), by and between BRAEBURN PHARMACEUTICALS, INC., a corporation formed under the laws of Delaware (“Braeburn”), and KNIGHT THERAPEUTICS INC., a corporation incorporated under the laws of Canada (“Knight”).
ASSET PURCHASE AND SALE AGREEMENT by and betweenPurchase Agreement • December 9th, 2016 • Braeburn Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This ASSET PURCHASE AND SALE AGREEMENT (this “Agreement”) is entered into as of November 4, 2014, by and between Endo Pharmaceuticals Solutions Inc., a company duly incorporated under the laws of Delaware (“Seller”), and Braeburn Pharmaceuticals BVBA SPRL, a private limited liability company existing under the laws of Belgium (“Buyer”). Hereinafter, “Parties” shall mean Seller and Buyer together, and “Party” shall mean either Seller or Buyer, as the context requires.
LICENSE AGREEMENT by and between TITAN PHARMACEUTICALS, INC. and BRAEBURN PHARMACEUTICALS SPRL dated December 14, 2012License Agreement • December 9th, 2016 • Braeburn Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
THIS LICENSE AGREEMENT (the “Agreement”) is made as of December 14, 2012 (the “Effective Date”), by and between TITAN PHARMACEUTICALS, INC., a corporation organized and existing under the laws of the State of Delaware and having its principal office at 400 Oyster Point Blvd., Suite 505, South San Francisco, CA 94080-1921, United States (“Titan”), and BRAEBURN PHARMACEUTICALS SPRL, a limited liability company organized and existing under the laws of Belgium and having its principal office at Jipfa Building, 3rd Floor, 142 Main Street, Tortola, British Virgin Islands (“Braeburn”).
PRODUCT PURCHASE AND PHARMACY SERVICES AGREEMENTProduct Purchase and Pharmacy Services Agreement • December 9th, 2016 • Braeburn Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS PRODUCT PURCHASE AND PHARMACY SERVICES AGREEMENT (this “Agreement”) between BRAEBURN PHARMACEUTICALS, INC., located at 47 Hulfish St., #441, Princeton, NJ 08542 (“Manufacturer”), and AVELLA OF DEER VALLEY, INC., located at 1606 W Whispering Wind Drive, Second Floor, Phoenix, AZ 85085, (together with its Approved Facilities “Pharmacy”), is effective as of September 1, 2016 (the “Effective Date”). Manufacturer and Pharmacy may be referred to individually in this Agreement as “Party” or collectively “Parties”.
ASSIGNMENT AND ASSUMPTION AGREEMENTAssignment and Assumption Agreement • December 9th, 2016 • Braeburn Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This ASSIGNMENT AND ASSUMPTION AGREEMENT (this “Agreement”), effective as of October 31 2014, is made and entered into by and between Braeburn Pharmaceuticals BVBA SPRL, a private limited liability company existing under the laws of Belgium (“Braeburn”), and FX Therapeutics, Inc., a Delaware corporation (“FX”). Braeburn and FX are sometimes referred to herein as a “Party” or collectively as the “Parties.”
SUPPLY AGREEMENT (LZ#49700)Supply Agreement • December 9th, 2016 • Braeburn Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
LICENSE AGREEMENT BY AND BETWEEN CAMURUS AB AND BRAEBURN PHARMACEUTICALS BVBA SPRL NOVEMBER 14, 2014License Agreement • December 9th, 2016 • Braeburn Pharmaceuticals, Inc. • Pharmaceutical preparations • England
This License Agreement is made as of the 14th day of November, 2014 (the “Effective Date”) between Camurus AB, a limited liability company organized and existing under the laws of Sweden and having its principal place of business at Ideon Science Park, Sölvegatan 41, SE-223 70 Lund, Sweden (“Camurus”) and Braeburn Pharmaceuticals BVBA SPRL, a private limited company organized and existing under the laws of Belgium and having its principal place of business at Louizalaan 209 A, 1050 Brussels, Belgium (“Braeburn”) (each a “Party” and collectively, the “Parties”).
